Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
about
Medication Access in America and Medicare Part D: Prescription Shopping Saves but May Be Costly.New tools for old drugs: Functional genetic screens to optimize current chemotherapy.Financial toxicity and implications for cancer care in the era of molecular and immune therapies.Conflict of interest among Italian medical oncologists: a national survey.Detection of a novel, primate-specific 'kill switch' tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53
P2860
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Research and Development Spend ...... et and Revenues After Approval
@nl
Research and Development Spend ...... t and Revenues After Approval.
@en
type
label
Research and Development Spend ...... et and Revenues After Approval
@nl
Research and Development Spend ...... t and Revenues After Approval.
@en
prefLabel
Research and Development Spend ...... et and Revenues After Approval
@nl
Research and Development Spend ...... t and Revenues After Approval.
@en
P2860
P1476
Research and Development Spend ...... t and Revenues After Approval.
@en
P2093
Sham Mailankody
Vinay Prasad
P2860
P304
P356
10.1001/JAMAINTERNMED.2017.3601
P577
2017-09-11T00:00:00Z